For most of the last two decades, DNA vaccines have been a technology perpetually described as promising but not quite there, but hat may be changing.
A wave of recent trial results and manufacturing advances suggests synthetic DNA platforms are being put to two distinct tests at once: whether they can produce vaccines that protect against entire families of viruses rather than single strains, and whether they can be manufactured fast enough to matter in an outbreak.
Designing against virus families, not single strains
The most immediate example comes from DIOSynVax, a University of Cambridge spin-out. A phase 1 trial of the company's pan-sarbecovirus vaccine, a synthetic DNA candidate designed to protect against SARS, SARS-CoV-2, and related coronaviruses rather than a single strain, was recently published in the Journal of Infection. According to Bio-IT World's coverage of the trial, the vaccine was administered through a jet of air targeting immune cells in the skin, and was shown to be safe, with participants developing measurable immune responses to the vaccine's broad targets.
The approach behind the vaccine, according to company cofounder Jonathan Heeney, uses artificial intelligence to analyze genetic sequence data pulled from across an entire virus family and identify stable, conserved features that AI models then use to computationally design synthetic antigens. Heeney told Bio-IT World that the original COVID-19 vaccines were built around a single viral isolate and a single target protein, the spike protein of the Wuhan-1 strain, and that by the time those vaccines reached the public, the virus had already mutated past that original design, requiring years of reformulation and repeated booster campaigns. The company's current priority is a "supra-seasonal" influenza vaccine intended to protect against a broader range of variants than the three-strain seasonal flu shots in use today, with Heeney noting that preclinical animal data suggest protection could last several years rather than a single season, though that timeline hasn't yet been tested in people.
Testing the same platform against older, harder threats
While DIOSynVax's approach represents a forward-looking bet on broad protection, synthetic DNA is also being tested more incrementally against specific pathogens that have resisted conventional vaccine development. A phase 1b trial of INO-4500, a synthetic DNA vaccine encoding a glycoprotein precursor from the Lassa virus, was conducted in 220 healthy adults in Ghana and published in Frontiers in Immunology in October 2025. Participants received either a 1 mg or 2 mg dose, or placebo, administered intradermally followed by electroporation, a technique that uses a brief electrical pulse to improve how efficiently cells take up the DNA. The vaccine was well tolerated, with no Grade 3 or higher treatment-related adverse events and 88.6 percent of all adverse events classified as Grade 1. Both dosing groups showed statistically significant increases in Lassa virus-specific binding antibodies at six and twelve weeks compared to placebo, with the higher dose producing the strongest response, and T-cell responses remained elevated above baseline through 48 weeks, indicating durable cellular immunity.
Lassa fever, endemic to parts of West Africa, has no approved vaccine, and trials like this one illustrate a use case for synthetic DNA that gets less attention than pandemic-scale ambitions: filling gaps in vaccine coverage for diseases that don't generate the commercial urgency of a global outbreak but still cause substantial regional mortality.
The manufacturing bottleneck synthetic DNA is trying to solve
Underneath both of these trials is a manufacturing story that matters just as much as the antigen science. Most mRNA vaccines, including the COVID-19 vaccines that reached the public in 2020 and 2021, rely on plasmid DNA as a starting material, genetic instructions produced through bacterial fermentation that can take over 30 days to manufacture, according to the Coalition for Epidemic Preparedness Innovations (CEPI). That timeline sits squarely on what CEPI has called the critical path to faster vaccine development under its 100 Days Mission, a goal endorsed by the G7 and G20 to compress vaccine development timelines to just over three months following identification of a new pandemic threat.
CEPI has funded multiple efforts across the industry to replace that bottleneck with enzymatic, cell-free DNA production methods that skip bacterial fermentation entirely. These approaches are designed to produce high-quality DNA template in days rather than weeks, with a smaller manufacturing footprint, lower cost, and less dependence on the specialized facilities and highly trained staff that traditional plasmid production requires. That combination matters most in regions where vaccine manufacturing infrastructure is less established, since a cell-free, enzymatic process is inherently easier to scale into new geographies than a fermentation-dependent one.
That shift extends beyond mRNA vaccine feedstock. Synthetic DNA formats are increasingly being used as a manufacturing input for therapeutics more broadly, not just vaccines, with regulatory agencies beginning to accept drug master files for GMP-grade synthetic DNA production and the first therapeutics built on these formats now advancing through clinical development in the United States and Europe.
What it means for drug developers
Taken together, these developments point to synthetic DNA maturing along two separate but related tracks. On the antigen design side, AI-assisted approaches are being used to move away from single-strain, single-target vaccines toward candidates intended to hold up against an entire viral family, a shift that, if it continues to bear out in later-phase trials, could change how often certain vaccine categories need to be reformulated. On the manufacturing side, enzymatic and cell-free DNA production methods are attacking one of the more stubborn timeline constraints in the vaccine development pipeline, the weeks-long plasmid fermentation step that sits upstream of mRNA and DNA vaccine candidates alike.
Neither track is fully proven yet. The DIOSynVax pan-sarbecovirus data is early-phase, and the company's more ambitious supra-seasonal flu candidate hasn't entered clinical trials. The Lassa virus trial, while encouraging on safety and durability, is a Phase 1b result and doesn't yet establish clinical efficacy against actual infection. And enzymatic DNA manufacturing platforms, while further along commercially than they were even two years ago, are still working through regulatory pathways designed around conventional plasmid production. For drug developers watching this space, the more concrete near-term signal may be less about any single vaccine candidate and more about whether faster, enzymatic DNA manufacturing can genuinely compress the timelines that have made rapid outbreak response so difficult to achieve in practice.
